Technology Provides Access to Patients Living Far from Study Site
Today, AMC Health announced the first patient enrolled in a prostate cancer clinical trial deploying televideo, at Mount Sinai's Icahn School of Medicine in Manhattan. The trial is testing whether the antidiabetic medication metformin may slow the progression of recurrent prostate cancer. AMC Health, a leading provider of proven mobile health solutions, has pioneered the use of televideo in clinical trials and is providing this capability for the study.
Matthew Galsky, M.D., Associate Professor of Medicine at Icahn School of Medicine, Director of Genitourinary Medical Oncology at Tisch Cancer Center at Mount Sinai and the principal investigator, said, "Our prior research demonstrates that geographic barriers and travel burdens prevent many patients from participating in clinical trials. This televideo technology by AMC Health provides a solution, connecting patients remotely with our study site. Patients living at great distances from Mount Sinai may come for an initial visit, but may be unable to travel monthly for follow-up visits, preventing them from participating in clinical trials. 'Video visits' make their participation possible."
The protocol for the trial was developed with input from patients, physicians and researchers, using an innovative crowd-sourcing platform developed by Transparency Life Sciences, a New York-based open-source pharmaceutical development company. "I developed a draft protocol," Dr. Galsky explained, "and 'the crowd' used Transparency's Internet platform to make significant improvements to the trial design."
"This study introduces innovative technologies that can improve future clinical trials," according to John Holland, Senior VP for Research in the Clinical Trials Division of AMC Health, "and we are honored to partner with Dr. Galsky and Mount Sinai in this effort."
Tweet This: Innovative #ClinicalTrial creates possible new treatment for prostate #cancer |http://bit.ly/1tE5k7o @AMCHealth @MountSinaiNYC #telehealth
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.